Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 8/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.56 |
| ▸ | MEN1 | O00255 | 7/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 4/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | SMO | Q99835 | 3/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | CKS1B | P61024 | 1/20 | 0.46 |
| ▸ | SKP1 | P63208 | 1/20 | 0.46 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1267482 | 0.84 | NPSR1 (0.56) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1267484 | 0.84 | NPSR1 (0.59) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL1267666 | 0.83 | NPSR1 (0.55) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| Hydrochloric Acid SCHEMBL1267654 | 0.83 | NPSR1 (0.58) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1267418 | 0.80 | NPSR1 (0.59) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1268636 | 0.80 | NPSR1 (0.59) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1268633 | 0.78 | NPSR1 (0.57) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1268195 | 0.77 | NPSR1 (0.74) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1268380 | 0.74 | NPSR1 (0.68) | NPSR1KMT2AMEN1SMN1; SMN2HTT | |
| SCHEMBL1267013 | 0.74 | NPSR1 (0.72) | NPSR1KMT2AMEN1SMN1; SMN2HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7981892-B2 | Disubstituted phthalazine hedgehog pathway antagonists | ELI LILLY AND COMPANY (US) | 2011-07-19 | — | — | US | disclosed |
| CN-102066353-A | Disubstituted phthalazine Hedgehog pathway antagonists | LILLY CO ELI | 2011-05-18 | — | — | CN | disclosed |
| US-20110046143-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | ELI LILLY AND COMPANY (US) | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046143-A1 | DISUBSTITUTED PHTHALAZINE HEDGEHOG PATHWAY ANTAGONISTS | SHH, GLI1, SMO | NPSR1 1903/4885KMT2A 590/4885MEN1 2224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.